Platform Of Chinese Health Sector Is Interested In Aragón City Mark1199. The digital transformation of health services would involve an investment of 32 million and the generation of 1,000 jobs.
Representatives of the Aragón Medical City and representatives of the largest Chinese health platform, the China Medical City (CMC), have held an online meeting in order to present the project promoted by the Aragon Health Cluster (Arahealth) and the Chambers of Aragon, which raises the concentration of health resources to create a powerful health ecosystem in the Aragonese community.
The purpose of the presentation, which took place at the Zaragoza Chamber, was to inspire Aragón for its project on a successful platform such as the CMC, in addition to establishing synergies and spaces for collaboration between the two organizations.
The main objective of the Aragón Medical City is to implement digital transformation in both public and private health services, which would involve an investment of 32 million euros and the creation of more than 1,000 jobs, as indicated in a note from press. Platform Of Chinese Health Sector Is Interested In Aragón City Mark1199. The digital transformation of health services would involve an investment of 32 million and the generation of 1,000 jobs.
The president of Arahealth and member of the executive committee of the Zaragoza Chamber, Javier Ruiz Poza, Carlos Lapuerta Castillejo, also from Arahealth, as well as José Luis Rubio, from Zeumat, who has promoted the meeting and who works actively in promoting the Aragon Health City.
From China, Luis Miguel Rubio, CEO of Zeumat, has participated, who has introduced the representatives of the Asian platform, Chen Xin, on behalf of the CMC; Vivid Li, CEO of the biomedical company LinkGen Biotech; Lei Wang, General Manager of Taizhou Gouda Health Management CO, and Phoenix Wang, of Nanjing Vazyme Medical Technology. At the closing, the Commissioner for the 2030 Agenda of the Government of Aragon, Fermín Serrano, who has supported this meeting, spoke.